Daraxonrasib FDA Access Authorization: A 40-Year Silence in Pancreatic Cancer Is Broken

Five-Year Survival of 3% — Unchanged for 50 Years

Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 92% of all pancreatic cancers. The frightening feature of the disease is its near absence of early symptoms: approximately 80% of patients are diagnosed at an advanced or metastatic stage. According to US data for 2025, the 5-year survival rate for metastatic PDAC is only around 3%. This figure has remained largely unchanged over the past 50 years — it is still one of the most common causes of cancer death.

Even standard first-line treatment in oncology (FOLFIRINOX, gemcitabine + nab-paclitaxel) provides limited benefit. Conroy and colleagues' 2011 PRODIGE 4/ACCORD 11 study (FOLFIRINOX versus gemcitabine) increased median overall survival to 11.1 months; this was a record achievement in the oncology history of pancreatic cancer, but still less than a year. In previously treated patients with metastatic PDAC, median overall survival was around 6-7 months; second-line treatment options (liposomal irinotecan + 5-FU in NAPOLI-1) offered limited benefit. Daraxonrasib demonstrating 13.2 months of survival — in previously treated patients — is therefore a truly unprecedented achievement in modern oncology.

An Oncogene “Thought to Be Undruggable”

RAS is one of the most important molecules in the history of modern oncology. In 1982, the laboratories of Robert Weinberg, Geoffrey Cooper, and Mariano Barbacid identified HRAS and KRAS as the first validated oncogenes in human cancers. This was a turning point in medical history: there was now molecular evidence that cancer was caused by “acquired genetic mutations.” For the next 40 years, oncology research sought a way to reach the RAS protein. Yet, because of its structure, RAS appeared to be an “undruggable” target.

RAS proteins (KRAS, NRAS, HRAS) are molecular switches that alternate between GTP-bound (active, “on”) and GDP-bound (inactive, “off”) forms. Oncogenic mutations (changes at positions G12, G13, Q61) keep this switch permanently “on” — continuously signaling. The problem was that the RAS protein surface lacked conventional pockets to which small molecules could attach; moreover, RAS binds GTP with picomolar affinity, making competitive inhibition practically impossible. Oncology therefore explored indirect approaches throughout the 1990s and 2000s: farnesyl transferase inhibitors, MEK inhibitors, PI3K inhibitors, and synthetic lethality strategies. None provided sufficient clinical benefit.

From the Traditional Approach to the Tri-Complex Mechanism

First-generation KRAS G12C inhibitors such as sotorasib and adagrasib bind covalently to the inactive (GDP-bound) form of the RAS protein; mutant RAS is trapped in this inactive state and removed from the signaling cycle. This approach worked clinically — but had an important limitation: it is effective only in the G12C mutation (cysteine-specific covalent binding requires a cysteine residue). Only about 1% of RAS mutations in pancreatic cancer are G12C; most are G12D (~40%), G12V (~30%), and G12R (~15%). Sotorasib was therefore usually not an option for pancreatic cancer patients.

Revolution Medicines' RAS(ON) tri-complex inhibitor platform broke through this limitation. It works differently in mechanistic terms:

The scientific roots of this approach lie in the “natural product chemistry” platform developed by Warp Drive Bio, which Revolution Medicines acquired in 2018. Chemical manipulation of cyclosporin A and other macrocyclic natural products opened the molecular door to this class of tri-complex drugs.

The Clinical Meaning of “Unprecedented”

RASolute 302 (NCT06625320) enrolled patients with metastatic PDAC who had received one prior line of systemic treatment and was designed as a global, randomized, open-label, phase 3 registration study. Patients were randomized 1:1 to either oral daraxonrasib 300 mg once daily or the investigator's choice of standard chemotherapy (5-FU/leucovorin/oxaliplatin, FOLFIRI, gemcitabine alone, nal-IRI/5-FU). The primary endpoints in patients with tumors harboring a RAS G12 mutation were progression-free survival (PFS) and overall survival (OS). The secondary endpoint concerned the entire randomized population (intent-to-treat, ITT) — all patients with and without RAS mutations.

Results of the first interim analysis announced by Revolution Medicines on 13 April 2026:

These figures fully deserve the description “extraordinary” for pancreatic cancer. HR 0.40 represents an effect size that modern oncology has never previously achieved in any randomized PDAC study. For comparison: erlotinib + gemcitabine (PA.3 study, 2007), HR 0.82; nab-paclitaxel + gemcitabine (MPACT, 2013), HR 0.72; FOLFIRINOX (PRODIGE 4, 2011), HR 0.57. Daraxonrasib monotherapy thus shows an even stronger result than the benefit achieved by intensive three-drug chemotherapy — and in the second-linesetting.

“Compassionate Use” — Access Before Approval

The FDA's Expanded Access Program (EAP — sometimes also called “compassionate use”) is a special arrangement allowing eligible patients outside clinical trials to receive an investigational drug that has not yet obtained full approval. It has three basic conditions:

EAP is not a clinical trial; data collection may not be mandatory except in exceptional circumstances. However, patient monitoring, reporting of adverse effects, and controlled drug distribution are mandatory. Revolution Medicines stated in its press release that “we are moving as quickly as possible to ensure safe and equitable access for eligible patients.”

Not Only Pancreatic Cancer — All RAS-Dependent Cancers

Pancreatic cancer is the “North Star” of RAS-dependent cancers — more than 90% of cases harbor a RAS mutation. However, other major solid tumors also depend on RAS:

Revolution Medicines has three main RAS(ON) inhibitors in its pipeline: daraxonrasib (RMC-6236) multi-selective (G12X, G13X, Q61X); elironrasib (RMC-6291) G12C-selective; zoldonrasib (RMC-9805) G12D-selective. In the next 2-3 years, a targeted treatment option may therefore enter clinical practice regardless of the RAS variant. Likewise, combination strategies for RAS-dependent cancers (anti-PD-1, CDK4/6, MEK inhibitor, anti-EGFR) are expanding through clinical trials.

Excitement, but Caution

This article is intended for medical news and information and does not provide individual treatment guidance. Daraxonrasib is currently only an investigational drug; the US Expanded Access Program (EAP) provides eligible patients with early access outside clinical trials through a physician's application. In Turkey, the individual use authorization process depends on assessment by the Ministry of Health, and the cost is borne by the patient. Pancreatic cancer treatment should be selected by a multidisciplinary oncology board, assessing the patient's clinical condition, performance status, previous treatment history, RAS mutation profile, and other biomarkers. Editor's note: The article is based on the FDA EAP authorization announcement dated 4 May 2026, the Revolution Medicines press release of 13 April 2026, and preliminary results of the RASolute 302 (NCT06625320) study; the full data will be presented at the ASCO 2026 Annual Meeting Plenary Session (31 May 2026).